Effect of erythropoietin-stimulating agent on uremic inflammation

The goal of the present study was to explore the effect of medications that are commonly prescribed for CKD patients on uremic state. This was a cross-sectional study. From January 2006 to October 2009, 1,623 patients with end-stage kidney disease (ESKD) commenced hemodialysis (HD) at the 9 particip...

Full description

Saved in:
Bibliographic Details
Published in:Journal of inflammation (London, England) England), 2012-05, Vol.9 (1), p.17-17, Article 17
Main Authors: Tanaka, Yuri, Joki, Nobuhiko, Hase, Hiroki, Iwasaki, Masaki, Ikeda, Masato, Ando, Ryoichi, Shinoda, Toshio, Inaguma, Daijo, Sakaguchi, Toshifumi, Komatsu, Yasuhiro, Koiwa, Fumihiko, Yamaka, Toshihiko, Shigematsu, Takashi
Format: Article
Language:English
Subjects:
ACE-I/ARB
Albumin
Analysis
Angiotensin
Blood cell count
Blood pressure
C-reactive protein
Calcium channels
Chronic kidney failure
CRP
Drug therapy
Erythropoietin
Erythropoietin stimulating agent
Health aspects
Hospitals
Inflammation
Initiation of dialysis
Internal medicine
Kidney diseases
Low density lipoproteins
Medicine
Oxidative stress
Regression analysis
Vitamin D
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The goal of the present study was to explore the effect of medications that are commonly prescribed for CKD patients on uremic state. This was a cross-sectional study. From January 2006 to October 2009, 1,623 patients with end-stage kidney disease (ESKD) commenced hemodialysis (HD) at the 9 participating hospitals. The criteria for exclusion from the database were 1) serum C-reactive protein (CRP) > 3 mg/dL, 2) WBC count > 9,000/mm3 or
ISSN:1476-9255
1476-9255
DOI:10.1186/1476-9255-9-17